Bosch Packaging Technology presents data mining service, which has recently been added to the range of pharma services. The aim is to evaluate existing machine data more effectively to identify and eliminate root causes.
The measures taken by Roszdravnadzor in 2017 allowed to withdraw 915 batches of medicinal products with substandard quality, which is 0.34% of the total number of batches released into circulation in that year.
The Coordination Group for Mutual Recognition and Decentralised Procedures - Human has endorsed EMA’s recommendation to withdraw the marketing authorisation for the pain medicine, because of the risk of serious liver injury.
The Russian Minister of Health deposited the instrument of ratification on the counterfeiting of medical products and crimes involving threats to public health with the Secretary General of the Council of Europe.
For incomplete or distorted provision of details, which caused harm to the life or health of citizens, the draft law establishes the administrative liability in the form of a fine ranging from one million to five million rubles.
The members of the Russian State Duma propose to introduce severe penalties, including imprisonment of up to 12 years, for the distribution of falsified medicinal products and medical devices via the Internet.
The amount of substandard medicines available on the market has been halved in 2017, while some falsified drugs get into circulation via the Internet, said Mikhail Murashko, the Head of Roszdravnadzor.
STADA Arzneimittel AG was informed by Gedeon Richter Plc. that the European Medicines Agency (EMA) has accepted the regulatory resubmission of its proposed biosimilar to Amgen's Neulasta (pegfilgrastim).